RankAlpha logo
Back to Rankings

EYPT

EyePointB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Primary sources support a real late-stage setup: LUGANO and LUCIA are fully enrolled, DME Phase 3 has started, March 31, 2026 cash and investments were presented as about $220M+, and the 10-K reported $306.1M at December 31, 2025 with runway into Q4 2027. If wet AMD data are positive, EYPT can rerate quickly because DURAVYU is the core value driver.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.6.
What can break
COMO/CAPRI enrollment or execution slippage reducing second-indication optionality
Momentum
61
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $30.00 · Bear $8.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $40.50
Why
Momentum61 · Δ7d +10.5
Value41 · Δ7d -0.1
Sentiment67 · Δ7d +7.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
61
26% active weight
Current posture
7d trendSoftening
Δ7d
+10.5
Δ21d
+26.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
67
34% active weight
Current posture
7d trendImproving
Δ7d
+7.6
Δ21d
+1.2
Why this grade

Composite grade B. Momentum 60.7 / Value 41.1 / Sentiment 67.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.12B
Beta
1.78
Shares Out
83.84M
P/E (TTM) · Derived
-4.2
P/S (TTM)
34.08
P/FCF (TTM) · Derived
-3.79
Rev YoY
-97.2%
EPS YoY
+52.3%
Gross Margin
+56.5%
Op Margin
-515.7%
Net Debt
-$283.29M
Current Ratio
6.66
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology